Erasca Hit With Class Action Lawsuit After Patient Death, IP Dispute Triggered $2.8B Market Cap Drop
ERAS has more than doubled off its 52-week low of $1.21.
Summary
Erasca, Inc. is now facing a securities class action lawsuit. This follows the company's April 27th 8-K disclosing an intellectual property dispute with Revolution Medicines and the April 28th news of a patient death in a clinical trial for its ERAS-0015 drug. These disclosures led to a 48% stock drop and a $2.8 billion loss in market capitalization. The lawsuit alleges Erasca misled investors regarding ERAS-0015's safety and IP protection, introducing new legal costs and potential liabilities. The lead plaintiff deadline for the class action is August 10, 2026.
At the time of this announcement, ERAS was trading at $13.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $1.21 to $24.28. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.